John CarrollOvjeren akaunt

@JohnCendpts

Founder of Endpoints News: Daily blast of biopharma bidness news. 18 years of context. 71,000+ subscribers. john@endpointsnews.com

Dorset, VT
Vrijeme pridruživanja: siječanj 2010.

Tweetovi

Blokirali ste korisnika/cu @JohnCendpts

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @JohnCendpts

  1. Prikvačeni tweet

    You know you want to :) Don’t miss my new daily biotech email from Endpoints — starts June 20. Sign up here:

    Poništi
  2. proslijedio/la je Tweet

    Thanks so much, Steven. We're so glad you love it. We run the masthead twice a year in print. But here it is on : .

    Poništi
  3. #3 UPDATED: Gilead surges wildly as world scrambles to counter a likely coronavirus pandemic while GSK pitches in on vaccine R&D campaign By and I

    Poništi
  4. #2 -- exclusive The power of precedent: How a one-off decision by Janet Woodcock established an unintended fast pathway at the FDA — what will follow?

    Poništi
  5. Top 3 stories today -- #1 Catalent chief John Chiminski triggers a $315M-plus wager on the booming cell therapy market now in the making - brought to you first by

    Poništi
  6. Of course, Tex-Mex food down by the Mexican border, Lyle Lovett on the play list and cold Dos Equis in the frig is ample compensation for the move ahead

    Poništi
  7. Looks like I bought a house in Texas today, going back to splitting my time between Vermont and the Lone Star State so my wife can tend to her ailing mother. Like so many others know, family care is essential in the US, where healthcare is dysfunctional

    Poništi
  8. FDA's Janet Woodcock had told colleagues that use of the dystrophin surrogate was a one-off for eteplirsen only. And then it wasn't. lessons learned

    Poništi
  9. proslijedio/la je Tweet
    prije 14 sati

    Revolution Medicines shoots for $150 million IPO; Novartis vet heads to Boston Pharma

    Poništi
  10. proslijedio/la je Tweet
    prije 14 sati

    Failed pivotal study? You can still have breakthrough therapy status — FDA signals to Resverlogix

    Poništi
  11. proslijedio/la je Tweet
    prije 14 sati

    How much does it cost to bootstrap a gene therapy startup? Not too much if you're Jim Wilson, per Passage Bio's $125M IPO filing

    Poništi
  12. United Therapeutics' drug fails PhII/III cancer trial, marking their second straight stumble in push beyond PAH

    Poništi
  13. Roche vet Sandra Horning jumps on biopharma board no. 3 — what’s that worth?

    Poništi
  14. Some retirement, Gilead, EQRx and now Moderna. Sandra is in demand.

    Poništi
  15. News -- Catalent chief John Chiminski triggers a $315M-plus wager on the booming cell therapy market now in the making

    Poništi
  16. proslijedio/la je Tweet
    prije 19 sati

    The biopharma industry saw the most bankruptcies occur since 2011 even without incl the reverse mergers. Complete list and data from in . 3 antibiotics companies unfortunately.

    Poništi
  17. proslijedio/la je Tweet
    prije 19 sati

    The power of precedent: How a one-off decision by Janet Woodcock established an unintended fast pathway at the FDA — what will follow?

    Poništi
  18. Why can't we do simple pandemic preparedness work

    Poništi
  19. This is the sort of thing that should be expected. Pandemic fear 101. Masks evaporate from shelves. They were laughing about it at my pharmacy.

    Poništi
  20. Congrats to the Chiefs for a big comeback win last night. That's the stuff.

    Poništi
  21. This is important -- The power of precedent: How a one-off decision by Janet Woodcock established an unintended fast pathway at the FDA — what will follow?

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·